US 11,939,329 B2
PARP1 inhibitors and uses thereof
Robert L. Hoffman, San Diego, CA (US); Porino Jinjo Va, San Diego, CA (US); Joseph Robert Pinchman, San Diego, CA (US); Lynnie Trzoss, San Diego, CA (US); Qing Dong, San Diego, CA (US); and Stephen W. Kaldor, Foster City, CA (US)
Assigned to XinThera, Inc., Foster City, CA (US)
Filed by XinThera, Inc., San Diego, CA (US)
Filed on Jan. 20, 2023, as Appl. No. 18/099,770.
Claims priority of provisional application 63/376,338, filed on Sep. 20, 2022.
Claims priority of provisional application 63/301,907, filed on Jan. 21, 2022.
Prior Publication US 2023/0234952 A1, Jul. 27, 2023
Int. Cl. C07D 471/04 (2006.01); C07D 401/12 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 401/12 (2013.01); C07B 2200/05 (2013.01)] 5 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.